Durect: Seeking to Initiate Phase 3 Registrational Trial for Larsucosterol With Topline Results Expected Within Two Years of Initiation >DRRX
Durect: Seeking to Initiate Phase 3 Registrational Trial for Larsucosterol With Topline Results Expected Within Two Years of Initiation >DRRX
Durect：寻求启动Larsucosterol的3期注册试验，预计在启动后两年内获得非临床试验结果>DRRX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间